Triple negative breast cancer: any closer to cracking the code?

Area of Science:

• Oncology
• Medical Research

Background:

• Triple negative breast cancer (TNBC) is an aggressive subtype with limited targeted treatment options.
• TNBC historically has a worse prognosis compared to other breast cancer subtypes.

Purpose of the Study:

• To review novel targeted therapies for triple negative breast cancer.
• To highlight recent advancements in treating this aggressive cancer subtype.

Main Methods:

• Literature review of recent studies on TNBC treatments.
• Focus on immunotherapy, antibody-drug conjugates, and PARP inhibitors.

Main Results:

• Immunotherapy is a key treatment for PD-L1 positive metastatic TNBC and high-risk localized TNBC.
• PARP inhibitors and new antibody-drug conjugates offer improved outcomes for both localized and metastatic TNBC.
• These advanced therapies represent recent breakthroughs, not previously available.

Conclusions:

• Emerging targeted therapies are transforming TNBC treatment paradigms.
• These novel agents provide new hope and improved prognosis for TNBC patients.
• Continued research into targeted therapies is crucial for advancing breast cancer care.